Hideyuki Iwayama1, Xiao-Hui Liao1, Lyndsey Braun2,3, Soledad Bárez-López4,5, Brian Kaspar2,3, Roy E Weiss6, Alexandra M Dumitrescu1, Ana Guadaño-Ferraz4,5, Samuel Refetoff1,7,8. 1. 1 Department of Medicine, The University of Chicago , Chicago, Illinois. 2. 2 Research Institute at Nationwide Children's Hospital , Columbus, Ohio. 3. 3 Department of Neuroscience, The Ohio State University , Columbus, Ohio. 4. 4 Institute for Biomedical Research "Alberto Sols," Consejo Superior de Investigaciones Científicas-Universidad Autónoma de Madrid , Madrid, Spain . 5. 5 Center for Biomedical Research on Rare Diseases (Ciberer), Instituto de Salud Carlos III , Madrid, Spain . 6. 6 Department of Medicine, University of Miami , Miami, Florida. 7. 7 Department of Pediatrics, The University of Chicago , Chicago, Illinois. 8. 8 Department of Committee on Genetics, The University of Chicago , Chicago, Illinois.
Abstract
BACKGROUND: MCT8 gene mutations produce thyroid hormone (TH) deficiency in the brain, causing severe neuropsychomotor abnormalities not correctable by treatment with TH. This proof-of-concept study examined whether transfer of human MCT8 (hMCT8) cDNA using adeno-associated virus 9 (AAV9) could correct the brain defects of Mct8 knockout mice (Mct8KO). METHODS: AAV9 vectors delivering long and/or short hMCT8 protein isoforms or an empty vector were injected intravenously (IV) and/or intracerebroventricularly (ICV) into postnatal day 1 Mct8KO and wild type (Wt) mice. Triiodothyronine (T3) was given daily for four days before postnatal day 28, at which time brains were collected after perfusion to assess increase in T3 content and effect on the T3-responsive transcription factor, Hairless. RESULTS: Increased pup mortality was observed after IV injection of the AAV9-long hMCT8 isoform, but not after injection of AAV9-short hMCT8 isoform. Compared to IV, ICV delivery produced more hMCT8 mRNA and protein relative to the viral dose, which was present in various brain regions and localized to the cell membranes. Despite production of abundant hMCT8 mRNA and protein with ICV delivery, only IV delivered AAV9-hMCT8 targeted the choroid plexus and significantly increased brain T3 content and expression of Hairless. CONCLUSIONS: These results indicate that MCT8 delivery to brain barriers by IV but not ICV injection is crucial for its proper function. MCT8 has no constitutive activity but acts through an increase in T3 entering the brain tissue. Increasing MCT8 expression in brain cell membranes, including neurons, is insufficient to produce an effect without an increase in brain T3 content. The correct hMCT8 isoform along with an optimized delivery method are critical for an effective gene therapy to provide functional MCT8 in the brain of patients with MCT8 mutations.
BACKGROUND:MCT8 gene mutations produce thyroid hormone (TH) deficiency in the brain, causing severe neuropsychomotor abnormalities not correctable by treatment with TH. This proof-of-concept study examined whether transfer of humanMCT8 (hMCT8) cDNA using adeno-associated virus 9 (AAV9) could correct the brain defects of Mct8 knockout mice (Mct8KO). METHODS:AAV9 vectors delivering long and/or short hMCT8 protein isoforms or an empty vector were injected intravenously (IV) and/or intracerebroventricularly (ICV) into postnatal day 1 Mct8KO and wild type (Wt) mice. Triiodothyronine (T3) was given daily for four days before postnatal day 28, at which time brains were collected after perfusion to assess increase in T3 content and effect on the T3-responsive transcription factor, Hairless. RESULTS: Increased pup mortality was observed after IV injection of the AAV9-long hMCT8 isoform, but not after injection of AAV9-short hMCT8 isoform. Compared to IV, ICV delivery produced more hMCT8 mRNA and protein relative to the viral dose, which was present in various brain regions and localized to the cell membranes. Despite production of abundant hMCT8 mRNA and protein with ICV delivery, only IV delivered AAV9-hMCT8 targeted the choroid plexus and significantly increased brain T3 content and expression of Hairless. CONCLUSIONS: These results indicate that MCT8 delivery to brain barriers by IV but not ICV injection is crucial for its proper function. MCT8 has no constitutive activity but acts through an increase in T3 entering the brain tissue. Increasing MCT8 expression in brain cell membranes, including neurons, is insufficient to produce an effect without an increase in brain T3 content. The correct hMCT8 isoform along with an optimized delivery method are critical for an effective gene therapy to provide functional MCT8 in the brain of patients with MCT8 mutations.
Authors: Caterina Di Cosmo; Xiao-Hui Liao; Alexandra M Dumitrescu; Nancy J Philp; Roy E Weiss; Samuel Refetoff Journal: J Clin Invest Date: 2010-08-02 Impact factor: 14.808
Authors: Beatriz Morte; Ainhoa Ceballos; Diego Diez; Carmen Grijota-Martínez; Alexandra M Dumitrescu; Caterina Di Cosmo; Valerie Anne Galton; Samuel Refetoff; Juan Bernal Journal: Endocrinology Date: 2010-03-08 Impact factor: 4.736
Authors: Kevin D Foust; Desirée L Salazar; Shibi Likhite; Laura Ferraiuolo; Dara Ditsworth; Hristelina Ilieva; Kathrin Meyer; Leah Schmelzer; Lyndsey Braun; Don W Cleveland; Brian K Kaspar Journal: Mol Ther Date: 2013-09-06 Impact factor: 11.454
Authors: Charles F Verge; Daniel Konrad; Michal Cohen; Caterina Di Cosmo; Alexandra M Dumitrescu; Teresa Marcinkowski; Shihab Hameed; Jill Hamilton; Roy E Weiss; Samuel Refetoff Journal: J Clin Endocrinol Metab Date: 2012-09-19 Impact factor: 5.958
Authors: Kathrin Meyer; Laura Ferraiuolo; Leah Schmelzer; Lyndsey Braun; Vicki McGovern; Shibi Likhite; Olivia Michels; Alessandra Govoni; Julie Fitzgerald; Pablo Morales; Kevin D Foust; Jerry R Mendell; Arthur H M Burghes; Brian K Kaspar Journal: Mol Ther Date: 2014-10-31 Impact factor: 11.454
Authors: Edith C H Friesema; Annette Grueters; Heike Biebermann; Heiko Krude; Arpad von Moers; Maarten Reeser; Timothy G Barrett; Edna E Mancilla; Johan Svensson; Monique H A Kester; George G J M Kuiper; Sahila Balkassmi; André G Uitterlinden; Josef Koehrle; Patrice Rodien; Andrew P Halestrap; Theo J Visser Journal: Lancet Date: 2004 Oct 16-22 Impact factor: 79.321
Authors: Artemis D Gika; Ata Siddiqui; Anthony J Hulse; Selvakumari Edward; Penny Fallon; Meriel E McEntagart; Wajanat Jan; Dragana Josifova; Tally Lerman-Sagie; James Drummond; Edward Thompson; Samuel Refetoff; Carsten G Bönnemann; Heinz Jungbluth Journal: Dev Med Child Neurol Date: 2009-10-07 Impact factor: 5.449
Authors: Alfonso Massimiliano Ferrara; Xiao-Hui Liao; Pilar Gil-Ibáñez; Teresa Marcinkowski; Juan Bernal; Roy E Weiss; Alexandra M Dumitrescu; Samuel Refetoff Journal: Endocrinology Date: 2013-05-21 Impact factor: 4.736
Authors: Soledad Bárez-López; Meredith D Hartley; Carmen Grijota-Martínez; Thomas S Scanlan; Ana Guadaño-Ferraz Journal: Thyroid Date: 2018-06-29 Impact factor: 6.568
Authors: Xiao-Hui Liao; Pablo Avalos; Oksana Shelest; Raz Ofan; Michael Shilo; Catherine Bresee; Shibi Likhite; Jean-Philippe Vit; Heike Heuer; Brian Kaspar; Kathrin Meyer; Alexandra M Dumitrescu; Samuel Refetoff; Clive N Svendsen; Gad D Vatine Journal: Thyroid Date: 2022-05-20 Impact factor: 6.506
Authors: Carmen Grijota-Martínez; Soledad Bárez-López; Eva Ausó; Samuel Refetoff; William H Frey; Ana Guadaño-Ferraz Journal: PLoS One Date: 2020-07-20 Impact factor: 3.240
Authors: Soledad Bárez-López; Carmen Grijota-Martínez; Xiao-Hui Liao; Samuel Refetoff; Ana Guadaño-Ferraz Journal: PLoS One Date: 2019-12-06 Impact factor: 3.240
Authors: Ferdy S van Geest; Nilhan Gunhanlar; Stefan Groeneweg; W Edward Visser Journal: Front Endocrinol (Lausanne) Date: 2021-09-01 Impact factor: 5.555
Authors: Carmen Grijota-Martínez; Soledad Bárez-López; David Gómez-Andrés; Ana Guadaño-Ferraz Journal: Front Neurosci Date: 2020-04-28 Impact factor: 4.677